{"organizations": [], "uuid": "65b2d4016f0d6018501ddb4d69e5c761364a90ad", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180223.html", "section_title": "Archive News &amp; Video for Friday, 23 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-sun-pharmaceutical-industries-says/brief-sun-pharmaceutical-industries-says-u-s-fda-issued-form-483-with-3-observations-for-halol-facility-idUSFWN1QD0JG", "country": "US", "domain_rank": 408, "title": "BRIEF-Sun Pharmaceutical Industries Says U.S. FDA Issued Form 483 With 3 Observations For Halol Facility", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-02-23T16:59:00.000+02:00", "replies_count": 0, "uuid": "65b2d4016f0d6018501ddb4d69e5c761364a90ad"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-sun-pharmaceutical-industries-says/brief-sun-pharmaceutical-industries-says-u-s-fda-issued-form-483-with-3-observations-for-halol-facility-idUSFWN1QD0JG", "ord_in_thread": 0, "title": "BRIEF-Sun Pharmaceutical Industries Says U.S. FDA Issued Form 483 With 3 Observations For Halol Facility", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "gujarat", "sentiment": "none"}, {"name": "india", "sentiment": "none"}], "organizations": [{"name": "brief-sun pharmaceutical industries says u.s. fda", "sentiment": "negative"}, {"name": "reuters) - sun pharmaceutical industries ltd", "sentiment": "neutral"}, {"name": "fda", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 23 (Reuters) - Sun Pharmaceutical Industries Ltd :\n* SUN PHARMACEUTICAL INDUSTRIES -U.S. FDA CONDUCTED GMP INSPECTION OF HALOL FACILITY (GUJARAT, INDIA) FROM FEBRUARY 12-23, 2018\n* AT CONCLUSION OF INSPECTION, AGENCY ISSUED A FORM 483, WITH THREE OBSERVATIONS\n* SUN PHARMACEUTICAL INDUSTRIES - CO PREPARING RESPONSE TO FDA OBSERVATIONS, TO BE SUBMITTED WITHIN 15 BUSINESS DAYS Source text - bit.ly/2EXxdbY Further company coverage:\n ", "external_links": ["http://bit.ly/2EXxdbY", "http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-23T16:59:00.000+02:00", "crawled": "2018-02-24T13:25:00.005+02:00", "highlightTitle": ""}